CSL’s first gene therapy for haemophilia B approved
Boost for effected patients as HEMGENIX receives green light from European Commission
Read More
Tag: Haemophilia
Sanofi’s efanesoctocog alfa may be game-changer for haemophilia A patients
Phase 3 study demonstrated that efanesoctocog alfa met both primary and secondary endpoints
Read More
Takeda findings may minimise haemophilia treatment side effects
Research from Takeda and Institute Krems Bioanalytics of IMC Krems and will help treat patients
Read More
Novo Nordisk release results from haemophilia treatment study
Data shows a significant reduction in treated spontaneous and traumatic bleeds among haemophilia patients
Read More
Novo Holdings establishes rare bleeding disorder firm Hemab
New company will focus on developing bispecific antibodies for rare bleeding disorders
Read More
Successful Elocta bid should widen access to the drug in the UK
Through an agreement with the NHS and Sobi UK, people living with haemophilia A in the UK will have increased access to Elocta following a successful bid in the UK’s Haemophilia A Tender
Read More
Novo cancels haemophilia drug Phase III trial
Haemophilia is a mostly inherited genetic disorder that impairs the body’s ability to make blood clots.
Read More
UK green light for Roche’s purchase of Spark
The Competition and Markets Authority has unconditionally approved the deal
Read More
Roche presents positive late-stage Hemlibra data
Haemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly.
Read More
Roche’s Hemlibra shows sustained bleed control in children
Roche’s Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.
Read More
Priority review for Roche’s Hemlibra
Roche’s Hemlibra will get a speedy review in the US for adults and children with haemophilia A without factor VIII inhibitors.
Read More
Trial findings back wider use of Roche’s Hemlibra
Data from two late-stage studies further support use of Roche’s Hemlibra in a much broader population of haemophilia patients.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
